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Aim of the work: To assess the serum level of FGF-23 in systemic sclerosis (SSc) patients (both
diffuse dSSc and limited lSSc subtypes) in order to ﬁnd if it has a role in the pathogenesis of the
disease and study its relation to the clinical manifestations.
Patients and methods: The study included 30 dSSc patients, 30 lSSc and 28 age and sex matched
controls. In patients, clinical examination and laboratory investigations were performed and
Medsger severity scale assessed. Serum FGF-23 was measured using ELISA.
Results: The age of dSSc patients was 36.94 ± 9.89 years and the lSSc 38.36 ± 10.04 years. The
serum FGF-23 level was 23.44 ± 14.86 pg/ml in dSSc patients, 20.01 ± 13.92 pg/ml in lSSc patients
and 23.09 ± 11.45 pg/ml in the control (p= 0.58). No signiﬁcant difference in the FGF-23 level
was found according to the presence of lung ﬁbrosis (p= 0.6). There was no signiﬁcant difference
in FGF levels among patients according to the severity (p= 0.39). In SSc patients there was a sig-
niﬁcant correlation between FGF and serum phosphorus especially in dSSc patients (r= 0.6,
p= 0.003). Serum urea signiﬁcantly correlated with FGF-23 in those with dSSc (r= 0.46,
p= 0.037). There was no signiﬁcant difference in the FGF-23 levels (p= 0.18) between those with
a normal and impaired glomerular ﬁltration rate.
106 S. Shenavandeh et al.Conclusion: The mean serum level of FGF-23 in this study showed no signiﬁcant difference
between systemic sclerosis patients and their subtypes with the normal subjects. It seems to have
no role in the clinical manifestations of the disease.
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Systemic sclerosis (SSc) is a chronic multisystem autoimmune
disease that has multiple overlapping and poorly deﬁned clin-
ical subsets [1]. The etiology of SSc is not still well elucidated,
but the dominant phenomena are immunologic mechanisms,
vascular endothelial cell injury, and activation of ﬁbroblasts
[2]. It is primarily a vascular disease that is mediated by auto-
immunity and results in tissue ﬁbrosis. The pathological ﬁnd-
ings in SSc skin document the signiﬁcant loss of the
peripheral vascular network, [3]. Altered balance of the oppos-
ing pro- and anti-angiogenic activities in SSc leads to abnor-
mal new vessel growth (angiogenesis) or defective repair
processes with subsequent tissue ischemia and ﬁbrosis [4]. Even
though the prognosis of the disease largely depends on visceral
involvement, musculoskeletal affection is more frequent than
expected in SSc patients with even reports on subclinical
arthritis and presents a major cause of disability [5]. Cardio-
vascular and pulmonary involvements occur in SSc patients
and asymptomatic coronary artery abnormalities are not
uncommon [6,7].
Calcinosis cutis, deposition of calcium salts (calcium phos-
phate, hydroxyapatite) in the skin and subcutaneous tissues
are common features of connective tissue diseases such as
SSc, dermatomyositis and overlap syndromes [8–10]. Rela-
tively fewer cases have been reported in patients with systemic
lupus erythematosus (SLE) [11,12]. The pathophysiology of
calcinosis cutis remains unclear. It has been suggested that
alkaline phosphatase tissue activity may lead to hydrolysis of
extracellular pyrophosphates normally preventing calcium
deposition [13]. Alternatively, phosphate bound to denatured
proteins of necrotic cells, at sites of trauma or inﬂammation,
may serve as a nidus for dystrophic calciﬁcation [14].
Fibroblast growth factor 23 (FGF-23) is a 30 kDa secreted
protein, member of the FGF family, and is thought to be
actively involved in phosphate homeostasis and skeletogenesis
[15]. There are inactivating mutations in its gene which were
shown to be associated with an autosomal recessive disorder
characterized by hyperphosphatemia and ectopic calciﬁcations
due to its reduced biological activity [16]. In animal studies, its
effects were documented in FGF-23 null mice, with high serum
phosphate levels, possibly due to increased renal reabsorption
of phosphate, and increased vitamin D activity leading to soft
tissue calciﬁcations [17,18].
Circulating FGF-23 levels change by dietary phosphorus,
serum phosphorus, serum calcium, and 1,25-dihydroxyvitamin
D level[1,25(OH)2D3] [19–21]. In patients with chronic renal
failure, an increase in FGF-23 levels has been shown to ante-
date the development of secondary hyperparathyroidism and
may thus be beneﬁcial in predicting which patients will develop
this disorder [22]. Therefore, FGF-23 has emerged as an essen-
tial regulator of normal phosphate and 1,25(OH)2D3 homeo-
stasis. Phosphate and 1,25(OH)2D3 increase FGF-23 levels;FGF 23 then acts on the renal proximal tubule to suppress
the synthesis of 1,25(OH)2D3 and decrease the reabsorption
of phosphate. The interrelation between FGF-23, vitamin D
and soft tissue calciﬁcation is not yet clear. It was suggested
that the lack of FGF-23, through a negatively regulated circuit
of 1,25(OH)2D3 synthesis, was responsible for abnormal tissue
calciﬁcation [23,24]. In another study, FGF-23 levels have been
found to be independently associated with peripheral vascular
calciﬁcations in adult patients on hemodialysis [25], and also
with total body atherosclerosis/future heart failure in adult
chronic kidney disease patients [26,27]. It was seen that familial
tumoral calcinosis, characterized by periarticular calciﬁed
masses often localized in the hip, elbow or shoulder [28] can
be caused by mutation in the FGF-23 gene [16].
The level of FGF-23 was found to be signiﬁcantly increased
in patients with high atherosclerosis scores [29]. Data are con-
sistent with the ﬁndings that higher FGF-23 associates with
endothelium dysfunction [30,31]. Another point of view is that
vascular injury and activation are likely to be the initiating
events in systemic sclerosis. Evidence of vascular involvement
is early and widespread, and is associated with signiﬁcant clin-
ical sequelae. The initial vascular insult is apparently endothe-
lial cell injury, possibly triggered by unidentiﬁed serum
cytotoxic factors or some other causes [26].
To the best of our knowledge, there was no research about
the effect of FGF-23 in pathogenesis of calcinosis or endothe-
lial cell injury in patients with scleroderma, so we designed this
research to evaluate FGF-23 serum level in patients with lim-
ited and diffuse scleroderma compared to normal subjects.
2. Patients and methods
This study was conducted on 60 SSc patients; 30 with diffuse
cutaneous scleroderma (dSSc), 30 with limited cutaneous
scleroderma (lSSc) and 28 normal subjects selected by conve-
nient and sequential method. The patients were recruited from
the rheumatology clinic of the Hafez hospital of Shiraz afﬁli-
ated to Shiraz University of Medical Sciences from September
2009 to September 2010 based on the Leroy criteria for the
diagnosis of scleroderma [32]. The normal participants of the
study were chosen from blood donors referring to Blood
Transfusion Organization in Shiraz. All procedures of this
study were in accordance with the ethical standards of the Eth-
ics Committee of the Shiraz University of Medical Sciences
(Accepted proposal No. 90-5608) on human experimentation
and with the 1975 Helsinki Declaration. A written informed
consent was signed by the patients before inclusion in the
study.
Screening, demographic measurements, and clinical assess-
ment were performed by the rheumatologists involved in this
research protocol. The Medsger severity scale [33] was consid-
ered for the patients. The study groups were scleroderma
patients with the age of more than 16 years old and less than
Table 1 Correlation of the serum FGF-23 level and the
studied laboratory investigations in the patients and control
(n= 88).
Investigation FGF-23 (pg/ml)
r p
Albumin 0.14 0.28
ALP 0.09 0.49
Calcium 0.20 0.10
Creatinine 0.02 0.87
Glucose 0.03 0.8
Phosphorus 0.28 0.02
Urea 0.10 0.45
PTH 0.04 0.73
ALP: Alkaline phosphatase; PTH: Parathormone.
Table 2 Comparison of the laboratory investigation levels
between those systemic sclerosis (SSc) patients with normal and
high levels of FGF-23.
Investigation p value
Albumin 0.007
ALP 0.03
Calcium 0.57
Creatinine 0.74
Glucose 0.53
Phosphorus 1
Urea 0.61
PTH 0.69
ALP: Alkaline phosphatase; PTH: Parathormone.
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function (GFR< 60 ml/min/1.73 m2), diabetes mellitus, and
abnormal parathyroid function were excluded from the study.
In all cases, a blood sample was withdrawn in the morning
after an overnight fasting and stored at 70 C until assayed.
Patients and control subjects were matched for age and sex.
The sera were tested for serum creatinine, urea, albumin, cal-
cium, phosphorus, glucose, alkaline phosphatase (ALP), para-
thyroid hormone, and FGF-23. Calcium, phosphorus,
creatinine, ALP and albumin were determined with standard
automated equipment. Total calcium was corrected for vari-
ance in serum albumin by the formula: corrected total Ca
(mg/dl) = measured Ca (mg/dl) + 0.8 · [4  Alb (g/dl)]. The
intact PTH was measured using immunoradiometric assay
(Beckman Coulter, Immunotec, Czech Republic; normal range,
9–65 pg/ml). The Estimated creatinine clearance rate (eCCr)
using Cockcroft–Gault formula was checked to ﬁnd the
GFR of patients. Biologically active and intact FGF-23 in
the sera was measured by FGF-23 ELISA (Kinos, Japan)
according to the manufacturer’s recommendations.
FGF-23 refers to a control sample from 28 healthy individ-
uals, receiving no treatment whatsoever, with similar age and
sex distributions to the treatment sample, with a mean value
of 23.09 ± 11.45 ng/l (5.08–61.06).
2.1. Statistical analysis
The results were analyzed using SPSS (version 13.0).
Comparisons of data between groups were made by analysis
of variances (ANOVA). Pearson correlation was used for
detection of the relation between two variables. P value less
than 0.05 was considered as statistically signiﬁcant.
3. Results
Initially, 96 subjects were selected for the study, 32 cases in
each group: group 1: diffuse systemic sclerosis (dSSc), group
2: limited systemic sclerosis (dSSc) and group 3: normal sub-
jects). During the course of the study, 8 subjects were excluded
from the study for not showing up for tests. The ﬁnal popula-
tion in the study consisted of 88 subjects (6 males and 82
females); In groups 1 and 2 there were 28 females and 2 males
(F:M 14:1) and in the control there were 26 females and 2
males (F:M 13:1). The mean age of the patients in group 1
was 36.94 ± 9.89 years (18–55 year), group 2 was
38.36 ± 10.04 years (16–58 year) and for the control group
was 37.13 ± 9.65 years (18–56 year). There was no signiﬁcant
difference between the three groups (p> 0.5).
The range of FGF-23 in group 1 was 5.08–76.7 pg/ml,
(mean 23.44 ± 14.86 pg/ml; median 46.2); in group 2 the range
was 1.08–63.97 pg/ml (mean of 20.01 ± 13.92 pg/ml; median
39.5) and in the control it was 5.08–61.06 pg/ml (mean of
23.09 ± 11.45 pg/ml; median 47.6). There was no signiﬁcant
difference in the mean level of FGF-23 among the three groups
(p= 0.58); the differences between dSSc and lSSc (p= 0.29),
lSSc and control (p= 0.25) or between the dSSc and control
(p= 0.79) were insigniﬁcant.
There was no cardiac involvement in our scleroderma
patients. The FGF-23 level was not different between patients
with and without pulmonary manifestations including dysp-
nea, basilar rales, abnormal chest X-ray, high resolution CT(HRCT) chest or pulmonary function tests (p= 0.54). Unfor-
tunately, we do not have data on pulmonary hypertension
because our patients did not have pulmonary hypertension.
The HRCT chest of 20 patients showed lung ﬁbrosis (mean
FGF-23 18.1 ± 12.1 pg/ml) and the HRCT in another 2 did
not detect lung ﬁbrosis (mean FGF-23 12.5 ± 8.5 pg/ml).
The rest of the patients did not have an available HRCT chest.
Comparing the FGF-23 level among these groups showed
no signiﬁcant difference (p= 0.6). According to the Medsger
severity scale there was no signiﬁcant difference in FGF levels
among patients with different severities (p= 0.39).
The subjects were also tested for serum calcium, phospho-
rus, albumin, alkaline phosphatase (ALP), glucose, creatinine,
urea, and PTH (parathyroid hormone) and the glomerular ﬁl-
tration rate (GFR) was estimated. There was no signiﬁcant
correlation between FGF-23 and the previously mentioned
parameters with the exception of phosphorus (r= 0.28,
p= 0.02) (Table 1). On comparing the studied parameters,
there was a signiﬁcantly different level of serum albumin and
ALP between the patients and control (p= 0.007 and
p= 0.03 respectively), otherwise the other laboratory investi-
gations were comparable. In SSc patients there was a signiﬁ-
cant correlation between FGF levels and serum phosphorus
(r= 0.32, p= 0.02); this signiﬁcant correlation is especially
present in the dSSc patients (r= 0.6, p= 0.003) and not in
lSSc or controls. Serum urea signiﬁcantly correlated with
FGF-23 only in group 1 (r= 0.46, p= 0.037) but not in
groups 2 and 3. The GFR was checked in 44 patients with a
mean of 78.2 ± 15.9 ml/min (38.2–109.3 ml/min). There were
108 S. Shenavandeh et al.39 patients with GFR> 60 ml/min (81.5 ± 13.4 ml/min) and
5 with GFR< 60 (52.3 ± 8.3 ml/min). There was no signiﬁ-
cant difference in the FGF-23 levels (p= 0.18) between
these two groups (GFR< 60: 19.58 ± 12.55 pg/ml and
GFR> 60: 24.82 ± 5.05 pg/ml).
When patients were classiﬁed into patients with normal
and high FGF levels (FGF levels higher than control’s
mean ± 2SD), there were no differences in the laboratory ﬁnd-
ings between patients with normal and high levels of FGF
(Table 2). There was also no difference in the presence or
absence of lung abnormality between patients with high or
normal levels of FGF (p= 0.77 and p= 0.86, respectively).
4. Discussion
In systemic sclerosis, both subtypes of the disease (diffuse and
limited) showed susceptibility to calcinosis [8,9,34]. Vascular
injury and activation are also likely to be the initiating events
in systemic sclerosis [26]. The FGF-23 has emerged as an
essential regulator of normal phosphate and 1,25(OH)2D3
homeostasis and also a factor contributing to endothelial cell
dysfunction and atherosclerosis [16,29]. In the current study,
the serum level of FGF-23 is evaluated in 60 SSc patients (30
dSSc and 30 lSSc) and compared with control subjects for
the ﬁrst time.
In the present study, the serum FGF-23 levels showed a
wide range in all patients and controls but with no signiﬁcant
differences. There was no signiﬁcant difference in the FGF-23
levels between the dSSc and lSSc subtypes or with the controls.
There were no correlation between FGF-23 level and clinical
manifestations in the SSc patients. So this study did not show
that FGF-23 level could be a key factor in the processes of SSc
or have a role in the diffuse or limited subtypes. Future inves-
tigations are required to ﬁnd any role in the disease especially
in patients with obvious calcinosis or those with special mani-
festations like digital gangrene.
The results did not show a signiﬁcant correlation between
the serum FGF-23 level and any of the measured laboratory
investigations including calcium, albumin, alkaline phospha-
tase, creatinine, urea, glucose, and PTH in the SSc patients.
Only the serum phosphorus level signiﬁcantly correlated with
FGF-23 (r= 0.28, p= 0.02) especially in those with dSSc.
Additionally, a signiﬁcant correlation was shown between
the FGF-23 and the urea in dSSc patients (r= 0.46,
p= 0.037). It should be considered that these two factors were
in the normal range in all three groups. It is likely that increas-
ing the number of patients may verify results in future studies.
In one study conducted by Kojima et al. on chronic hemodial-
ysis patients, it was shown that the FGF-23 signiﬁcantly corre-
lated with serum creatinine (r= 0.42, p< 0.0001), albumin
(r= 0.23, p= 0.03), calcium (r= 0.39, p= 0.0001) and phos-
phorous (r= 0.74, p< 0.0001). There was a negative correla-
tion between FGF-23 and glucose (r= 0.23, p= 0.029) [35].
Results were different in our patients who did not have any
kidney problem, renal insufﬁciency or metabolic disease; there
was no correlation between the serum FGF-23 level and any of
the estimated investigations.
In conclusion, the mean serum level of FGF-23 in this study
showed no signiﬁcant difference between systemic sclerosis
patients and their subtypes with the normal subjects. It seems
to have no role in the clinical manifestations of the disease.Conﬂict of interest
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